Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 19, 2026
DataAggregated Company Financials
Companies550
  • 7D1.3%
  • 3M3.4%
  • 1Y31.1%
  • YTD2.4%

Over the last 7 days, the Biotech industry has risen 4.6%, driven by gains from Moderna of 29%. This takes the industry's 12 month performance to a gain of 30%. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 19 Jun 2026US$1.3tUS$170.0b-US$12,149,726,055.0216.5x-107.3x7.7x
Sun, 17 May 2026US$1.3tUS$170.3b-US$12,610,203,995.0017.2x-101.2x7.5x
Tue, 14 Apr 2026US$1.3tUS$166.2b-US$11,974,231,819.6917.7x-107.8x7.8x
Thu, 12 Mar 2026US$1.3tUS$169.1b-US$15,382,879,989.9921.5x-86.9x7.9x
Sat, 07 Feb 2026US$1.3tUS$164.5b-US$14,976,078,595.2422.8x-85.1x7.7x
Mon, 05 Jan 2026US$1.2tUS$163.5b-US$15,345,571,210.7721.1x-79x7.4x
Wed, 03 Dec 2025US$1.2tUS$163.6b-US$16,200,420,708.7119.2x-74.8x7.4x
Fri, 31 Oct 2025US$1.2tUS$164.1b-US$17,498,744,568.8517.4x-67.2x7.2x
Sun, 28 Sep 2025US$1.1tUS$163.5b-US$18,298,125,619.8316.3x-58.9x6.6x
Tue, 26 Aug 2025US$1.1tUS$163.6b-US$18,607,464,334.9015.2x-57.7x6.6x
Thu, 24 Jul 2025US$979.1bUS$155.2b-US$23,256,073,043.1517x-42.1x6.3x
Sat, 21 Jun 2025US$930.4bUS$155.9b-US$23,931,619,289.3716.8x-38.9x6x
Mon, 19 May 2025US$895.2bUS$155.9b-US$24,392,718,921.6016.3x-36.7x5.7x
Wed, 16 Apr 2025US$764.9bUS$119.2b-US$36,605,024,519.5620.2x-20.9x6.4x
Fri, 14 Mar 2025US$841.0bUS$118.5b-US$37,519,343,472.2717.8x-22.4x7.1x
Sun, 09 Feb 2025US$840.3bUS$117.3b-US$30,891,273,158.0417.2x-27.2x7.2x
Tue, 07 Jan 2025US$968.2bUS$149.6b-US$26,363,916,330.8816.7x-36.7x6.5x
Thu, 05 Dec 2024US$1.0tUS$150.0b-US$26,559,447,157.6617.4x-38.6x6.8x
Sat, 02 Nov 2024US$1.1tUS$147.4b-US$30,526,626,860.5217.5x-34.7x7.2x
Mon, 30 Sep 2024US$893.6bUS$113.2b-US$36,006,680,210.7121.3x-24.8x7.9x
Wed, 28 Aug 2024US$912.3bUS$113.2b-US$35,873,175,029.8023.7x-25.4x8.1x
Fri, 26 Jul 2024US$1.2tUS$164.3b-US$28,279,434,472.0928.4x-42.8x7.4x
Sun, 23 Jun 2024US$1.2tUS$164.4b-US$27,942,490,934.1228.1x-41.4x7x
Tue, 21 May 2024US$1.1tUS$164.6b-US$26,833,016,716.7724.2x-42.8x7x
Thu, 18 Apr 2024US$1.1tUS$164.2b-US$23,335,767,618.8220.4x-46.2x6.6x
Sat, 16 Mar 2024US$1.2tUS$167.4b-US$22,091,319,843.2913.9x-53.3x7x
Mon, 12 Feb 2024US$1.2tUS$169.3b-US$26,263,046,791.8719.8x-44.2x6.9x
Wed, 10 Jan 2024US$1.4tUS$204.8b-US$22,502,246,114.0020.4x-64.2x7.1x
Fri, 08 Dec 2023US$1.3tUS$204.6b-US$22,051,399,456.0019.3x-58.1x6.3x
Sun, 05 Nov 2023US$1.2tUS$206.7b-US$20,535,513,316.0018.8x-60.4x6x
Tue, 03 Oct 2023US$1.3tUS$207.3b-US$13,085,561,707.0016.8x-96x6.1x
Thu, 31 Aug 2023US$1.3tUS$207.7b-US$12,462,393,654.0017.6x-103.8x6.2x
Sat, 29 Jul 2023US$1.1tUS$186.0b-US$15,177,418,533.0014.7x-74.9x6.1x
Mon, 26 Jun 2023US$1.1tUS$186.2b-US$16,162,116,001.0013.6x-70.3x6.1x
Price to Earnings Ratio

-70.3x


Total Market Cap: US$1.1tTotal Earnings: -US$16,162,116,001.00Total Revenue: US$186.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -58.5x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.65%
Healthcare-2.14%
Biotech1.34%
Biotech1.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MRNA ModernaUS$63.9628.8%
+US$5.7b		151.8%PS11.4x
RVMD Revolution MedicinesUS$162.919.2%
+US$2.9b		308.0%PB23.1x
NTRA NateraUS$231.285.5%
+US$1.7b		35.3%PS13.2x
VRTX Vertex PharmaceuticalsUS$451.621.5%
+US$1.7b		0.7%PE26.4x
CYTK CytokineticsUS$78.7813.7%
+US$1.3b		140.7%PS101.1x

Latest News

LEGN
US$27.93
Legend Biotech
7D
-23.0%
1Y
-19.9%
QURE
US$46.37
uniQure
7D
72.9%
1Y
207.1%
ROIV
US$31.40
Roivant Sciences
7D
5.6%
1Y
174.5%
NTRA
US$231.28
Natera
7D
5.5%
1Y
35.3%
BIIB
US$196.58
Biogen
7D
-1.7%
1Y
55.4%
ABBV
US$216.49
AbbVie
7D
-3.7%
1Y
16.7%
CYTK
US$78.78
Cytokinetics
7D
13.7%
1Y
140.7%
NBIX
US$158.21
Neurocrine Biosciences
7D
-2.8%
1Y
24.3%
ONC
US$270.66
BeOne Medicines
7D
4.0%
1Y
7.1%
MRNA
US$63.96
Moderna
7D
28.8%
1Y
151.8%
INCY
US$98.22
Incyte
7D
-8.9%
1Y
43.9%
Analysis Article • Jun 17

Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results

Recent interest in Incyte (INCY) stock is closely tied to fresh clinical and regulatory milestones, including pivotal data for zilurgisertib in fibrodysplasia ossificans progressiva and Phase 3 results for tafasitamab plus lenalidomide with R-CHOP. See our latest analysis for Incyte. Incyte stock has cooled slightly in the very short term, with a 1-day share price return of 2.19% and a 7-day share price return of 5.35%. However, the 1-year total shareholder return of 46.11% and 3-year total...
AMGN
US$337.60
Amgen
7D
-4.6%
1Y
16.6%
VRTX
US$451.62
Vertex Pharmaceuticals
7D
1.5%
1Y
0.7%
Narrative Update • Jun 17

VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside

Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.
RVMD
US$162.91
Revolution Medicines
7D
9.2%
1Y
308.0%
ALNY
US$278.09
Alnylam Pharmaceuticals
7D
-3.9%
1Y
-11.0%
Narrative Update • Jun 16

ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing

The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.
GILD
US$123.76
Gilead Sciences
7D
-1.7%
1Y
14.6%